Retatrutide Long-Term Safety: 2-Year Follow-Up Data from Phase 3 Trials

Introduction

TRIUMPH-4 showed 28.7% weight loss at 68 weeks in December 2025. That's impressive, but it's not the full story. Obesity is a chronic disease requiring years of treatment, not months. The real question: What happens at 104 weeks? At 2 years? At 5 years?

As of January 2026, no published 2-year retatrutide data exists yet. TRIUMPH-4 was 68 weeks. The Phase 2 trial was 48 weeks. Extended follow-up studies are ongoing but haven't reported. However, we can analyze what we know from existing trials, compare to other GLP-1 medications with longer-term data, and identify the critical unknowns that matter for anyone considering this medication.

This article examines retatrutide's safety profile through 68 weeks, projects likely long-term outcomes based on similar medications, and honestly addresses what we don't yet know. Here's what the current data shows:

Source: TRIUMPH-4 Phase 3 trial (N=751, 12mg dose, 68 weeks). Longer-term data (2+ years) not yet published. Individual risk varies based on medical history and concurrent medications.

What We Know: Safety Data Through 68 Weeks

The longest published retatrutide trial is TRIUMPH-4 at 68 weeks (about 16 months). In that study of 751 participants on the 12mg dose, the safety profile looked similar to other GLP-1 receptor agonists but with one notable difference: dysesthesia, a tingling or altered sensation side effect that occurred in 20.9% of participants.

Most common side effects in TRIUMPH-4:

• Nausea: 43% (mostly during dose escalation, weeks 1-12)
• Diarrhea: 33% (peaks weeks 4-8, improves by week 16)
• Dysesthesia: 20.9% (tingling sensations, onset variable, persistence unknown)
• Vomiting: 18% (decreases after month 3)
• Constipation: 12%

Treatment discontinuation: 18.2% of participants stopped retatrutide due to side effects. That's higher than semaglutide (Wegovy) at 6.9% but comparable to tirzepatide (Zepbound) at 14.9%. Most discontinuations occurred in the first 24 weeks during dose escalation.

Serious adverse events: 8-10% of participants experienced a serious adverse event (SAE), defined as an event requiring hospitalization or medical intervention. The most common SAEs were gallbladder-related issues (cholecystitis, cholelithiasis) at 2.4%, consistent with other GLP-1 medications. Pancreatitis occurred in <1% of participants.

No deaths occurred in TRIUMPH-4 attributable to retatrutide. This is consistent with the broader safety profile of GLP-1 receptor agonists, which have not shown increased mortality risk in obesity trials.

The critical limitation: 68 weeks is not "long-term." Obesity requires years of treatment. We need 2-year, 5-year, and ideally 10-year data to fully understand retatrutide's safety profile over the treatment duration most patients will require.

Sustained Weight Loss: Does It Plateau or Continue?

TRIUMPH-4 showed continued weight loss through week 68, the trial's endpoint. The trajectory was:

• Week 24: 17.3% weight loss
• Week 48: 24.2% weight loss
• Week 68: 28.7% weight loss

The curve hadn't plateaued at week 68. Participants were still losing weight, albeit at a slower rate (about 0.3% per month in the final 12 weeks compared to 1.5% per month in weeks 12-24). This raises an important question: Does weight loss continue beyond 68 weeks, or does it plateau?

Comparison to tirzepatide (Mounjaro/Zepbound):

Tirzepatide's SURMOUNT-1 trial ran 72 weeks, showing 22.5% weight loss at the endpoint. Extended follow-up data through 88 weeks (unpublished, presented at conferences) suggested the plateau occurred around week 72-76, with minimal additional loss beyond that point.

If retatrutide follows a similar pattern, we'd expect:

• Maximum weight loss around weeks 72-80 (about 18-20 months)
• Estimated peak loss: 29-30% (modest increase from week 68's 28.7%)
• Maintenance phase: weeks 80+ with stable weight if treatment continues

But here's the unknown: Does the triple-agonist mechanism (GLP-1 + GIP + glucagon) produce a different long-term trajectory than dual agonists like tirzepatide? Glucagon's metabolic effects might sustain weight loss longer, or they might not. We simply don't know yet.

What we do know from other GLP-1 medications: Weight regain after stopping is near-universal. Semaglutide's STEP 1 trial showed participants regained two-thirds of lost weight within one year of stopping treatment. Retatrutide will likely follow the same pattern—this is a chronic medication, not a temporary intervention.

Dysesthesia: The Long-Term Question Mark

Dysesthesia—the altered sensation or tingling side effect—is retatrutide's unique concern. It occurred in 20.9% of TRIUMPH-4 participants, far higher than other GLP-1 medications (semaglutide: 2-3%, tirzepatide: 4-5%).

What dysesthesia looks like:

• Tingling or "pins and needles" sensations, most commonly in hands, feet, or face
• Altered temperature sensation (hot or cold sensitivity)
• Burning or prickling sensations
• Onset typically during dose escalation (weeks 4-16) but can occur later

Severity: Most cases were mild and didn't lead to treatment discontinuation. About 2% of participants stopped retatrutide specifically due to dysesthesia.

The critical unknown: Does it persist long-term?

TRIUMPH-4 tracked dysesthesia occurrence but didn't systematically follow whether it resolved after treatment or persisted. Some participants reported resolution by week 40-50. Others still experienced symptoms at week 68 when the trial ended. We don't know:

• What percentage of dysesthesia cases resolve vs. persist long-term?
• Does continued treatment worsen, improve, or stabilize symptoms?
• Do symptoms resolve after stopping retatrutide, or do they persist?
• Is there permanent nerve involvement, or is it reversible?

Why this matters: If dysesthesia persists indefinitely in even 5-10% of users, that's a significant long-term quality-of-life concern. Chronic tingling or altered sensation is manageable for some people, intolerable for others.

Mechanistic hypothesis: Dysesthesia may be related to glucagon receptor activation, which retatrutide targets but other GLP-1 medications don't. Glucagon affects peripheral nerve function and blood flow. This might explain why retatrutide has higher dysesthesia rates than semaglutide or tirzepatide.

What to monitor: If you're on retatrutide and experience dysesthesia, track:

• When it started (which dose, which week)
• Severity progression (stable, worsening, improving)
• Impact on daily activities
• Response to dose reduction (does lowering the dose help?)

Report persistent or worsening dysesthesia to your doctor. There's no established treatment, but some patients report improvement with dose reduction or temporary treatment interruption.

Cardiovascular Safety: Long-Term Heart Health

GLP-1 receptor agonists have demonstrated cardiovascular benefits in long-term trials. Semaglutide reduced major adverse cardiovascular events (MACE) by 20% in the SELECT trial. Tirzepatide's ongoing SURPASS-CVOT trial will provide similar data.

Retatrutide's cardiovascular trial: TRIUMPH-CVOT is ongoing, enrolling patients with obesity and established cardiovascular disease. Primary endpoint is MACE (cardiovascular death, myocardial infarction, stroke). Expected completion: 2027-2028.

What we know from TRIUMPH-4:

Blood pressure improvements were significant and sustained through 68 weeks:

• Systolic BP: -8.0 mmHg average reduction
• Diastolic BP: -4.3 mmHg average reduction

These reductions persisted even as weight loss plateaued in the final weeks, suggesting blood pressure benefits may be partially independent of weight loss—possibly due to direct GLP-1 and glucagon receptor effects on vascular function.

Heart rate: Increased by an average of 5-7 beats per minute, consistent with other GLP-1 medications. This is generally benign but requires monitoring in patients with pre-existing arrhythmias.

Lipid profile improvements:

• LDL cholesterol: -8% reduction
• Triglycerides: -22% reduction
• HDL cholesterol: +12% increase

These are favorable changes that reduce cardiovascular risk over time. The triglyceride reduction is particularly notable and likely related to glucagon receptor activation, which enhances fat oxidation.

Long-term cardiovascular unknowns:

Does retatrutide reduce cardiovascular events like semaglutide does, or is the benefit purely from weight loss and metabolic improvements? The triple-agonist mechanism could be neutral, beneficial, or (theoretically) harmful for CV outcomes beyond weight loss effects. TRIUMPH-CVOT will answer this question, but results are 2-3 years away.

For now, the surrogate markers (blood pressure, lipids, weight loss) all point in a favorable direction for cardiovascular health.

Gastrointestinal Effects: Tolerance and Adaptation

Nausea and diarrhea are the most common side effects, but they follow a predictable pattern that helps with long-term tolerance:

Weeks 1-8 (dose escalation): Highest incidence. Nausea peaked at 48% during weeks 4-6 when doses increased from 4mg to 8mg. Diarrhea peaked at 38% during the same period.

Weeks 8-24: Gradual improvement. By week 16, nausea had decreased to 22% and diarrhea to 18%. Most participants developed tolerance as their bodies adapted to GLP-1 receptor stimulation.

Weeks 24-68: Stable and low. By week 24, only 8-12% of participants reported ongoing nausea, and most rated it as mild. Diarrhea stabilized at 6-8%.

The pattern: Most GI side effects are worst during dose escalation and improve significantly within 3-6 months. This matches data from semaglutide and tirzepatide.

Long-term management strategies that help:

• Slow dose escalation (extend the 2mg and 4mg phases if needed)
• Take medication with food (even though it's not required, it helps some people)
• Avoid high-fat meals during dose increases
• Stay hydrated
• Over-the-counter anti-nausea aids (ginger, vitamin B6)

Gallbladder concerns:

GLP-1 medications increase gallbladder disease risk due to rapid weight loss and altered bile composition. Retatrutide showed a 2.4% rate of gallbladder-related adverse events (cholecystitis, gallstones requiring intervention) over 68 weeks.

This is slightly higher than the general population (0.5-1% annually) but consistent with other weight-loss medications. The risk appears related to the speed and magnitude of weight loss rather than a direct drug effect.

Who's at higher risk:

• Rapid weight loss (>2-3 pounds per week sustained)
• Personal or family history of gallstones
• Female sex
• Age >40
• Pre-existing obesity (paradoxically, heavier patients have higher baseline gallstone risk)

Monitoring: If you develop right upper quadrant abdominal pain, nausea after fatty meals, or yellowing of skin/eyes, report to your doctor immediately for gallbladder evaluation.

Metabolic Effects: Glucose Control and Diabetes Prevention

TRIUMPH-4 included both participants with and without type 2 diabetes. Metabolic improvements were substantial and sustained:

HbA1c reduction (diabetic participants):

• Baseline: 8.1% average
• Week 24: 6.2%
• Week 68: 5.9%

This represents near-normalization of blood glucose for most diabetic participants. About 78% achieved HbA1c <7% (diabetes treatment target), and 42% achieved <5.7% (non-diabetic range).

Fasting glucose reduction:

• Diabetic participants: -58 mg/dL average reduction
• Non-diabetic participants: -12 mg/dL average reduction

Diabetes prevention potential:

Among participants with prediabetes at baseline (HbA1c 5.7-6.4%), 89% reverted to normal glucose tolerance by week 68. Only 1.2% progressed to diabetes during the trial.

This suggests retatrutide may have powerful diabetes prevention effects beyond just weight loss. The GLP-1, GIP, and glucagon receptor activation all contribute to improved insulin sensitivity and beta-cell function.

Long-term unknowns:

• Do these metabolic improvements persist beyond 68 weeks?
• What happens if treatment is stopped—does diabetes risk return?
• Does retatrutide prevent diabetes long-term, or just delay it?

Based on tirzepatide data (SURMOUNT-1 showed sustained HbA1c reductions through 88 weeks), we'd expect metabolic benefits to persist as long as treatment continues and weight remains stable.

Cancer Risk: Theoretical Concerns and Current Data

GLP-1 receptor agonists have been scrutinized for potential cancer risk due to:

1. Thyroid C-cell tumors seen in rodent studies (medullary thyroid carcinoma)
2. Pancreatitis concerns, which theoretically increase pancreatic cancer risk
3. Rapid cell turnover during weight loss

Current retatrutide data (TRIUMPH-4, 68 weeks):

• Thyroid cancer: 0 cases
• Pancreatic cancer: 0 cases
• Other cancers: 3 cases (breast, colon, skin) — within expected population rates

The rodent thyroid tumor issue:

All GLP-1 receptor agonists cause C-cell hyperplasia and tumors in rats and mice at high doses. However, human thyroid C-cells express far fewer GLP-1 receptors than rodent cells. After 10+ years of semaglutide and liraglutide use in millions of patients, no thyroid cancer signal has emerged in humans.

Retatrutide carries the same FDA black box warning as other GLP-1 medications: contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis and pancreatic cancer:

Acute pancreatitis occurred in <1% of TRIUMPH-4 participants. This is consistent with other GLP-1 medications. Long-term studies of semaglutide and liraglutide (10+ years of post-market surveillance) have not shown increased pancreatic cancer risk.

The reassuring data:

Large-scale real-world studies of GLP-1 medications show either neutral or reduced cancer risk compared to other diabetes/obesity treatments. A 2023 meta-analysis of 30+ trials (200,000+ patients) found no increased cancer risk with GLP-1 receptor agonists.

What we don't know for retatrutide:

Does the glucagon receptor activation change cancer risk compared to pure GLP-1 agonists? Theoretically, glucagon stimulates lipolysis and metabolic rate, which might affect cell proliferation. We simply don't have long-term data yet.

Monitoring recommendation: Standard cancer screening based on age and risk factors. No additional screening is currently recommended for retatrutide users beyond general population guidelines.

Comparison to Other Weight-Loss Medications

How does retatrutide's safety profile compare to established medications? Here's the data:

Note: Discontinuation rates and adverse events from respective pivotal trials at highest approved doses.

Key takeaways from the comparison:

1. Retatrutide has the highest discontinuation rate among current weight-loss medications, primarily driven by GI side effects and dysesthesia.
2. Serious adverse event rates are comparable across all medications, suggesting retatrutide isn't fundamentally more dangerous—just less tolerable for some patients.
3. Dysesthesia is retatrutide-specific and the main differentiator in safety profiles. This is likely due to glucagon receptor activation.
4. Longer-term data exists for competitors: Semaglutide has 2-year trial data and 8+ years of real-world use. Retatrutide's longest trial is only 68 weeks.
5. The efficacy-tolerability trade-off: Retatrutide produces superior weight loss (28.7% vs. 15-22%) but with lower tolerability (18.2% vs. 7-15% discontinuation).

What Happens After Stopping Treatment?

This is perhaps the most important long-term question: Can you stop retatrutide after reaching your goal weight, or is it lifelong treatment?

Data from other GLP-1 medications:

Semaglutide's STEP 1 trial included a one-year follow-up after stopping treatment:

• Average weight regain: 11.6% of body weight (about two-thirds of what was lost)
• Metabolic improvements largely reversed (HbA1c, blood pressure, lipids returned toward baseline)
• GI side effects resolved within 2-4 weeks of stopping

Tirzepatide shows similar patterns based on preliminary data.

Why weight regain occurs:

GLP-1 receptor agonists don't "cure" obesity—they suppress appetite and slow gastric emptying while you're taking them. When you stop:

• Appetite returns to baseline (or higher, as the body tries to restore lost weight)
• Metabolic rate may decrease slightly from weight loss
• Without the medication's appetite-suppressing effects, maintaining the calorie deficit becomes extremely difficult

The "set point" theory: Your body defends a certain weight range through hormonal and metabolic adaptations. Losing weight triggers compensatory mechanisms (increased hunger, decreased metabolism) that persist long after weight loss. GLP-1 medications override these mechanisms temporarily.

What this means for retatrutide:

We don't have official data yet, but based on the mechanism (GLP-1 + GIP + glucagon receptor agonism), weight regain after stopping is near-certain. In fact, the glucagon component might make it worse—glucagon increases metabolic rate while on treatment, so stopping could cause a sharper metabolic drop than with pure GLP-1 agonists.

Potential strategies to minimize regain:

1. Gradual dose tapering: Some doctors recommend slowly reducing the dose over 3-6 months rather than stopping abruptly. This might help the body readjust, though data supporting this is limited.
2. Transition to maintenance medication: Switching to a lower-efficacy but better-tolerated medication (like semaglutide at a lower dose) might help maintain some weight loss.
3. Intensive lifestyle intervention: Combining stopping medication with aggressive diet/exercise support might help, but success rates are low (10-20% maintain most weight loss).
4. Intermittent treatment: Some propose using retatrutide cyclically (6-12 months on, 3-6 months off), but this hasn't been studied and might increase side effects with each restart.

The hard truth: For most people, retatrutide (like other GLP-1 medications) is lifelong treatment if you want to maintain the weight loss. This isn't a failure of willpower—it's the biology of obesity.

Who Should Not Take Retatrutide: Long-Term Contraindications

Beyond the standard contraindications (pregnancy, medullary thyroid cancer history, MEN 2), long-term safety concerns create additional relative contraindications:

Absolute contraindications (do not use):

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy within 2 months
• Severe gastroparesis or GI motility disorders
• History of severe pancreatitis

Relative contraindications (use with caution, close monitoring):

• History of gallbladder disease or gallstones
• Diabetic retinopathy (rapid glucose reduction can worsen retinal changes)
• Severe kidney disease (not studied in this population)
• History of eating disorders (appetite suppression might trigger relapse)
• Pre-existing peripheral neuropathy (dysesthesia concerns)
• Heart failure with reduced ejection fraction (limited data)

The dysesthesia factor:

Given retatrutide's 20.9% dysesthesia rate, anyone with pre-existing peripheral neuropathy, nerve damage, or chronic pain conditions should think carefully. Adding new tingling/altered sensations on top of existing nerve issues is a quality-of-life concern.

Age considerations:

TRIUMPH-4 included participants up to age 75, but the majority were under 65. Long-term safety in elderly patients (75+) is unknown. Older adults have higher baseline risk for:

• Falls (which could be worsened by dysesthesia affecting sensation)
• Malnutrition (if appetite suppression is too severe)
• Polypharmacy interactions

Medication interactions requiring monitoring:

• Insulin and sulfonylureas (hypoglycemia risk — may need dose reduction)
• Warfarin (GI effects can alter vitamin K absorption)
• Oral medications requiring careful timing (retatrutide slows gastric emptying)

Monitoring During Long-Term Treatment

If you start retatrutide, regular monitoring helps catch problems early:

Baseline (before starting):

• Comprehensive metabolic panel (kidney and liver function)
• HbA1c and fasting glucose
• Lipid panel
• Thyroid function (TSH at minimum)
• Pregnancy test (if applicable)
• Screen for gallbladder disease if symptomatic

First 6 months (dose escalation phase):

• Weight and blood pressure every 2-4 weeks
• HbA1c at 3 months (if diabetic)
• Metabolic panel at 3 months (kidney function monitoring)
• Assess for dysesthesia, GI tolerance, mood changes

Months 6-12:

• HbA1c every 3-6 months
• Metabolic panel every 6 months
• Lipid panel at 12 months
• Weight and blood pressure monthly

Long-term (12+ months):

• HbA1c every 6 months (or per doctor's recommendation)
• Metabolic panel annually
• Lipid panel annually
• Continue weight and blood pressure tracking

Red flags requiring immediate medical attention:

• Severe abdominal pain (especially right upper quadrant)
• Persistent vomiting or inability to keep fluids down
• Signs of pancreatitis (severe upper abdominal pain radiating to back)
• Yellowing of skin or eyes (jaundice)
• Severe dysesthesia interfering with daily activities
• Thoughts of self-harm or severe depression
• Rapid heart rate (>120 bpm at rest)
• Severe hypoglycemia (if diabetic)

The Unknowns: What We're Still Waiting to Learn

1. True 2-year data: TRIUMPH trials are ongoing with extended follow-up. We should have 104-week (2-year) data by late 2026 or early 2027.
2. Cardiovascular outcomes: TRIUMPH-CVOT results expected 2027-2028. This will definitively answer whether retatrutide reduces heart attacks and strokes or if the benefit is purely from weight loss.
3. Dysesthesia natural history: Does it resolve, persist, or worsen with continued treatment? Does it go away after stopping? Detailed neurological assessments are ongoing.
4. Cancer surveillance: 5-10 years of real-world data are needed to rule out rare cancer signals.
5. Pregnancy outcomes: What happens if someone gets pregnant while on retatrutide or shortly after stopping? Animal studies suggest potential harm, but human data is limited.
6. Very long-term weight maintenance: Can anyone maintain weight loss on retatrutide for 5-10 years? Does efficacy decline over time (tachyphylaxis)?
7. Rare events: With only ~5,000 patients in trials, we can't detect adverse events that occur in <1 in 1,000 people. Post-market surveillance will identify these.
8. Cost-benefit at scale: If millions use retatrutide for years, what's the public health impact? Do the cardiovascular and diabetes prevention benefits outweigh the side effect burden and cost?

Conclusion

Retatrutide's long-term safety profile is a mixed picture: impressive metabolic benefits and apparently low risk of severe harm, but higher discontinuation rates and unique dysesthesia concerns compared to other medications.

What we know:

• Gastrointestinal side effects are common but typically improve after 3-6 months
• No deaths or major safety signals through 68 weeks
• Metabolic improvements (glucose, blood pressure, lipids) are substantial and sustained
• Discontinuation rate of 18.2% is higher than competitors, mainly due to GI issues and dysesthesia

What we don't know:

• True 2+ year safety data
• Whether dysesthesia persists long-term or resolves
• Cardiovascular outcomes (trial ongoing)
• Weight regain trajectory after stopping (likely similar to other GLP-1 medications)
• Very rare adverse events that only emerge with large-scale use

The bottom line:

Retatrutide offers superior weight loss compared to existing medications, but with a trade-off in tolerability. For people who can tolerate the side effects (about 82% complete the full 68 weeks), it produces remarkable results with an acceptable safety profile based on current data.

For long-term use (years to decades), we're extrapolating from other GLP-1 medications, which have good safety records. But retatrutide's unique triple-agonist mechanism means we're in partly uncharted territory.

If you're considering retatrutide:

• Understand this is likely lifelong treatment if you want to maintain weight loss
• Know that 1 in 5 people stop due to side effects
• Be prepared for GI issues in the first 3-6 months
• Monitor for dysesthesia and report persistent symptoms
• Have regular medical follow-up to catch problems early

The risk-benefit calculation depends on your starting point. For someone with BMI >40 and diabetes, retatrutide's risks are clearly outweighed by benefits. For someone with BMI 32 and no complications, the calculation is more nuanced.

More data is coming. Extended follow-up studies will fill in the gaps over the next 2-3 years. For now, we're working with the best available evidence—and acknowledging where uncertainty remains.

Sources

This analysis is based on:

• Jastreboff AM, et al. "Retatrutide Phase 3 Results - TRIUMPH-4." Presented at Obesity Week 2025, December 2025
• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine 2023;389:514-526
• Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021 (STEP 1 trial)
• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022 (SURMOUNT-1)
• Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA 2021 (STEP 4 - withdrawal study)
• ClinicalTrials.gov: TRIUMPH Phase 3 program trial protocols and status updates
• FDA Prescribing Information: Wegovy, Mounjaro/Zepbound, Saxenda (for comparative safety data)
• FDA Briefing Documents: Endocrinologic and Metabolic Drugs Advisory Committee meetings on GLP-1 receptor agonists (2020-2023)